Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$3.06 +3.7%	$3.22	$2.07 ▼ $4.20	$95.02M	0.43	83,358 shs	57,081 shs
NNVC NanoViricides	$1.44 +5.1%	$1.50	$0.94 ▼ $2.07	$23.14M	0.96	242,025 shs	109,767 shs
SRZN Surrozen	$11.22 -1.1%	$9.46	$5.90 ▼ $18.17	$98.38M	0.6	14,779 shs	7,857 shs
XBIT XBiotech	$3.20	$2.94	$2.50 ▼ $8.32	$97.56M	0.97	37,722 shs	57,506 shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+3.73%	+3.03%	-9.47%	+22.40%	-2.24%
NNVC NanoViricides	+5.11%	-4.00%	-17.71%	-19.55%	-28.89%
SRZN Surrozen	-1.15%	+0.72%	+28.38%	+40.95%	+52.65%
XBIT XBiotech	0.00%	+1.59%	+3.23%	+12.68%	-51.29%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANIX Anixa Biosciences	2.4766 of 5 stars	3.5	3.0	0.8	3.3	0.0
NNVC NanoViricides	0.759 of 5 stars	0.0	5.0	2.5	0.0	0.0
SRZN Surrozen	2.7942 of 5 stars	3.5	2.0	2.9	3.3	0.0
XBIT XBiotech	1.7309 of 5 stars	0.0	4.0	2.8	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	3.00	Buy	$9.00	194.12% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A
SRZN Surrozen	3.00	Buy	$38.50	243.14% Upside
XBIT XBiotech	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest NNVC, XBIT, ANIX, and SRZN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
8/5/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/10/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/29/2025	ANIX Anixa Biosciences	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	$0.59 per share	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A
SRZN Surrozen	$12.62M	7.61	N/A	N/A	$5.50 per share	2.04
XBIT XBiotech	$4.01M	24.33	N/A	N/A	$5.68 per share	0.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$12.55M	-$0.38	N/A	∞	N/A	N/A	-68.17%	-60.38%	9/5/2025 (Estimated)
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A
SRZN Surrozen	-$63.56M	-$14.42	N/A	N/A	N/A	-274.42%	-545.43%	-64.40%	11/5/2025 (Estimated)
XBIT XBiotech	-$38.53M	-$0.92	N/A	∞	N/A	N/A	-15.60%	-14.64%	11/11/2025 (Estimated)

Latest NNVC, XBIT, ANIX, and SRZN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/5/2025	Q3 2025	ANIX Anixa Biosciences	-$0.10	N/A	N/A	N/A	N/A	N/A
8/13/2025	Q2 2025	XBIT XBiotech	N/A	-$0.06	N/A	-$0.06	N/A	N/A
8/8/2025	Q2 2025	SRZN Surrozen	-$1.23	-$1.14	+$0.09	$2.55	N/A	$0.98 million
6/3/2025	Q2 2025	ANIX Anixa Biosciences	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A
SRZN Surrozen	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.89	8.89
NNVC NanoViricides	N/A	3.44	2.47
SRZN Surrozen	N/A	16.41	16.41
XBIT XBiotech	N/A	40.16	40.16

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
NNVC NanoViricides	10.30%
SRZN Surrozen	66.57%
XBIT XBiotech	55.70%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	25.30%
NNVC NanoViricides	4.60%
SRZN Surrozen	45.18%
XBIT XBiotech	30.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	32.21 million	24.06 million	Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable
SRZN Surrozen	80	8.56 million	4.69 million	Not Optionable
XBIT XBiotech	100	30.49 million	21.10 million	Optionable

NNVC, XBIT, ANIX, and SRZN Headlines

Recent News About These Companies

XBiotech (NASDAQ:XBIT) Share Price Passes Above Fifty Day Moving Average - What's Next?

August 22 at 4:31 AM | marketbeat.com

XBiotech (NASDAQ:XBIT) Releases Quarterly Earnings Results

August 16, 2025 | marketbeat.com

XBiotech Inc. (NASDAQ:XBIT) Short Interest Up 452.0% in July

August 2, 2025 | marketbeat.com

XBiotech (NASDAQ:XBIT) Stock Price Passes Below Fifty Day Moving Average - Should You Sell?

August 1, 2025 | marketbeat.com

XBiotech (NASDAQ:XBIT) Shares Cross Below 50 Day Moving Average - Should You Sell?

July 23, 2025 | marketbeat.com

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

March 2, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

March 1, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 28, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 27, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 26, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 25, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 24, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 23, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 22, 2025 | accessnewswire.comA

An Investigation Has Been Launched Into XBiotech Inc. For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 21, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 20, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 18, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 17, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 16, 2025 | accessnewswire.comA

XBiotech Inc. Is Being Investigated For Securities Law Violations And Investors With Losses Are Urged To Contact The Schall Law Firm

February 15, 2025 | accessnewswire.comA

The Schall Law Firm Invites Shareholders With Losses In XBiotech Inc. To Join A Securities Fraud Investigation

February 14, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NNVC, XBIT, ANIX, and SRZN Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$3.06 +0.11 (+3.73%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.05 -0.01 (-0.33%)

As of 08/22/2025 05:55 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

NanoViricides NYSE:NNVC

$1.44 +0.07 (+5.11%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.46 +0.02 (+1.67%)

As of 08/22/2025 07:55 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

Surrozen NASDAQ:SRZN

$11.22 -0.13 (-1.15%)

As of 08/22/2025 04:00 PM Eastern

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

XBiotech NASDAQ:XBIT

$3.20 0.00 (0.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.24 +0.04 (+1.25%)

As of 08/22/2025 04:43 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time